| Title | Moxifloxacin: a respiratory fluoroquinolone. | | Author(s) | Miravitlles M, Anzueto A | | Institution | Servei de Pneumologia, Institut Clínic del Tòrax (IDIBAPS), Ciber de Enfermedades Respiratorias (CIBERES), Hospital Clínic, Barcelona, Spain. marcm@clinic.ub.es | | Source | Expert Opin Pharmacother 2008 Jul; 9(10):1755-72. | | Abstract | BACKGROUND: Respiratory quinolones are a class of antimicrobials with a high activity against most respiratory pathogens. Moxifloxacin is a fourth-generation fluoroquinolone that has been shown to be effective against Gram-positive, Gram-negative, and atypical strains, as well as multi-drug resistant Streptococcus pneumoniae.
OBJECTIVE: To review and update the clinical efficacy of moxifloxacin in the treatment of respiratory infections.
METHOD: To perform a systematic review of publications on the clinical efficacy of moxifloxacin in respiratory infections.
RESULTS: The clinical efficacy of moxifloxacin has been shown in controlled studies of community-acquired pneumonia, exacerbations of chronic bronchitis and acute bacterial rhinosinusitis. Moxifloxacin has demonstrated a faster resolution of symptoms in community-acquired pneumonia and exacerbations of chronic bronchitis patients compared with first-line therapy together with excellent eradication rates.
CONCLUSIONS: The use of moxifloxacin as first-line therapy for moderate to severe respiratory infections in the community and the hospital has been recognized in international guidelines. | | Language | eng | | Pub Type(s) | Journal Article
| | PubMed ID | 18570608 |
|
